Mark Ensor

Mark Ensor

Auto-generated profile, based on publicly available information

Mark Ensor

University of Kentucky

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 1997 in Trends in Biotechnology
Verified
Journal Article
Closed access
SRSridhar Ramanathan
Sridhar Ramanathan
MEMark Ensor
Mark Ensor
SDSylvia Daunert
Sylvia Daunert

1 July 2001 in Analytical Biochemistry
Verified
Journal Article
Closed access
LSLyndon L.E. Salins
Lyndon L.E. Salins
RWRachel A. Ware
Rachel A. Ware
CEC.MArk Ensor
C.MArk Ensor
SDSylvia Daunert
Sylvia Daunert

19 July 2011 in Annual Review of Analytical Chemistry
Verified
Journal Article
Closed access
DSDaniel Scott
Daniel Scott
EDEmre Dikici
Emre Dikici
MEMark Ensor
Mark Ensor
SDSylvia Daunert
Sylvia Daunert
There is an increasing need for versatile yet sensitive labels, posed by the demands for low detection in bioanalysis. Bioluminescent proteins have many desirable characteristics, including the ability to be detected at extremely low concentrations; no background interference from autofluorescent compounds present in samples; and compatibility with many miniaturized platforms, such as lab-on-a-chip and lab-on-a-CD systems. Bioluminescent proteins have found a plethora of analytical applications in intracellular monitoring, genetic regulation and detection, immuno- and binding assays, and whole-cell biosensors, among others. As new bioluminescent organisms are discovered and new bioluminescence proteins are characterized, use of these proteins will continue to dramatically improve our understanding of molecular and cellular events, as well as their applications for detection of environmental and biomedical samples.

4 September 2019 in Biology of Sex Differences
Verified
Journal Article
Open access
PDF file
RSRobin Shoemaker
Robin Shoemaker
LTLisa R. Tannock
Lisa R. Tannock
WSWen Su
Wen Su
MGMing Gong
Ming Gong
SGSusan B. Gurley
Susan B. Gurley
LCLisa A. Cassis
Lisa A. Cassis
Obesity increases the risk for hypertension in both sexes, but the prevalence of hypertension is lower in females than in males until menopause, despite a higher prevalence of obesity in females. We previously demonstrated that angiotensin-converting enzyme 2 (ACE2), which cleaves the vasoconstrictor, angiotensin II (AngII), to generate the vasodilator, angiotensin-(1-7) (Ang-(1-7)), contributes to sex differences in obesity-hypertension. ACE2 expression in adipose tissue was influenced by obesity in a sex-specific manner, with elevated ACE2 expression in obese female mice. Moreover, estrogen stimulated adipose ACE2 expression and reduced obesity-hypertension in females. In this study, we hypothesized that deficiency of adipocyte ACE2 contributes to obesity-hypertension of females. We generated a mouse model of adipocyte ACE2 deficiency. Male and female mice with adipocyte ACE2 deficiency or littermate controls were fed a low (LF) or a high fat (HF) diet for 16 weeks and blood pressure was quantified by radiotelemetry. HF-fed mice of each sex and genotype were challenged by an acute AngII injection, and blood pressure response was quantified. To translate these findings to humans, we performed a proof-of-principle study in obese transwomen in which systemic angiotensin peptides and blood pressure were quantified prior to and after 12 weeks of gender-affirming 17β-estradiol hormone therapy. Adipocyte ACE2 deficiency had no effect on the development of obesity in either sex. HF feeding increased systolic blood pressures (SBP) of wild-type male and female mice compared to LF-fed controls. Adipocyte ACE2 deficiency augmented obesity-induced elevations in SBP in females, but not in males. Obese female, but not obese male mice with adipocyte ACE2 deficiency, had an augmented SBP response to acute AngII challenge. In humans, plasma 17β-estradiol concentrations increased in obese transwomen administered 17β-estradiol and correlated positively with plasma Ang-(1-7)/AngII balance, and negatively to SBP after 12 weeks of 17β-estradiol administration. Adipocyte ACE2 protects female mice from obesity-hypertension, and reduces the blood pressure response to systemic AngII. In obese transwomen undergoing gender-affirming hormone therapy, 17β-estradiol administration may regulate blood pressure via the Ang-(1-7)/AngII balance.

10 January 2009 in Protein Engineering, Design and Selection
Verified
Journal Article
Open access
PDF file
EDE. Dikici
E. Dikici
XQX. Qu
X. Qu
LRL. Rowe
L. Rowe
LML. Millner
L. Millner
CLC. Logue
C. Logue
SDS. Daunert
S. Daunert
The photoprotein aequorin has been widely used as a bioluminescent label in immunoassays, for the determination of calcium concentrations in vivo, and as a reporter in cellular imaging. It is composed of apoaequorin (189 amino acid residues), the imidazopyrazine chromophore coelenterazine and molecular oxygen. The emission characteristics of aequorin can be changed by rational design of the protein to introduce mutations in its structure, as well as by substituting different coelenterazine analogues to yield semi-synthetic aequorins. Variants of aequorin were created by mutating residues His16, Met19, Tyr82, Trp86, Trp108, Phe113 and Tyr132. Forty-two aequorin mutants were prepared and combined with 10 different coelenterazine analogues in a search for proteins with different emission wavelengths, altered decay kinetics and improved stability. This spectral tuning strategy resulted in semi-synthetic photoprotein mutants with significantly altered bioluminescent properties.

1 September 2002
Verified
Journal Article
Closed access
JBJohn S Bomalaski
John S Bomalaski
FHFrederick W Holtsberg
Frederick W Holtsberg
CEC Mark Ensor
C Mark Ensor
MCMike A Clark
Mike A Clark